File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Arsenic trioxide in the treatment of haematological malignancies

TitleArsenic trioxide in the treatment of haematological malignancies
Authors
Issue Date2004
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eds
Citation
Expert Opinion On Drug Safety, 2004, v. 3 n. 6, p. 589-597 How to Cite?
AbstractArsenic trioxide (AS2O3) for leukaemia treatment was described a century ago. Recent resurgence in the use of arsenic trioxide is related to its high efficacy in acute promyelocytic leukaemia (APL). Most arsenic trioxide preparations are intravenous, although an oral formulation is similarly efficacious. Side effects of arsenic trioxide are usually minor, including skin reactions, gastrointestinal upset, and reversible increases in transaminases. During therapy, a leukocytosis occasionally occurs, which may be complicated by fluid accumulation and pulmonary infiltration. Arsenic trioxide causes an asymptomatic QT prolongation in most patients. However, if concomitant cardiopulmonary diseases or electrolyte disturbances are present, more sinister arrhythmias may develop. Therefore, before commencement of arsenic trioxide therapy, a full cardiac assessment and avoidance of drugs that prolong QT interval should be instituted. Arsenic trioxide is partly renally excreted and, therefore, dose adjustment is required when renal function is impaired. in addition to its use in APL, arsenic trioxide is now tested in other malignancies, notably multiple myeloma. © 2004 Ashley Publications Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/78070
ISSN
2015 Impact Factor: 2.896
2015 SCImago Journal Rankings: 1.029
References

 

DC FieldValueLanguage
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2010-09-06T07:38:50Z-
dc.date.available2010-09-06T07:38:50Z-
dc.date.issued2004en_HK
dc.identifier.citationExpert Opinion On Drug Safety, 2004, v. 3 n. 6, p. 589-597en_HK
dc.identifier.issn1474-0338en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78070-
dc.description.abstractArsenic trioxide (AS2O3) for leukaemia treatment was described a century ago. Recent resurgence in the use of arsenic trioxide is related to its high efficacy in acute promyelocytic leukaemia (APL). Most arsenic trioxide preparations are intravenous, although an oral formulation is similarly efficacious. Side effects of arsenic trioxide are usually minor, including skin reactions, gastrointestinal upset, and reversible increases in transaminases. During therapy, a leukocytosis occasionally occurs, which may be complicated by fluid accumulation and pulmonary infiltration. Arsenic trioxide causes an asymptomatic QT prolongation in most patients. However, if concomitant cardiopulmonary diseases or electrolyte disturbances are present, more sinister arrhythmias may develop. Therefore, before commencement of arsenic trioxide therapy, a full cardiac assessment and avoidance of drugs that prolong QT interval should be instituted. Arsenic trioxide is partly renally excreted and, therefore, dose adjustment is required when renal function is impaired. in addition to its use in APL, arsenic trioxide is now tested in other malignancies, notably multiple myeloma. © 2004 Ashley Publications Ltd.en_HK
dc.languageengen_HK
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/edsen_HK
dc.relation.ispartofExpert Opinion on Drug Safetyen_HK
dc.rightsExpert Opinion on Drug Safety. Copyright © Informa Healthcare.en_HK
dc.subject.meshAntineoplastic Agents - administration & dosage - adverse effects - pharmacology - therapeutic useen_HK
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - therapeutic useen_HK
dc.subject.meshArsenicals - administration & dosage - adverse effects - pharmacology - therapeutic useen_HK
dc.subject.meshClinical Trials as Topicen_HK
dc.subject.meshDrug Resistance, Neoplasmen_HK
dc.subject.meshHematologic Neoplasms - drug therapyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshOxides - administration & dosage - adverse effects - pharmacology - therapeutic useen_HK
dc.subject.meshRemission Inductionen_HK
dc.subject.meshSalvage Therapyen_HK
dc.subject.meshTretinoin - administration & dosageen_HK
dc.titleArsenic trioxide in the treatment of haematological malignanciesen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1474-0338&volume=3&spage=589&epage=597&date=2004&atitle=Arsenic+trioxide+in+the+treatment+of+haematological+malignanciesen_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/14740338.3.6.589en_HK
dc.identifier.pmid15500417en_HK
dc.identifier.scopuseid_2-s2.0-8844265256en_HK
dc.identifier.hkuros108026en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-8844265256&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume3en_HK
dc.identifier.issue6en_HK
dc.identifier.spage589en_HK
dc.identifier.epage597en_HK
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.citeulike48756-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats